(PharmaNewsWire.Com, August 13, 2018 ) Erythropoietin is present in the bone marrow cells controlling the production of red blood cells. They can be used for the treatment of anaemia, HIV and Cancer. Various synthetic forms of erythropoietin are available in the market due to advancements in recombinant DNA technology.
Erythropoietin Drugs Market was worth USD 9.94 billion in 2018 and estimated to be growing at a CAGR of 9.7%, to reach USD 15.79 billion by 2023.
Increased incidence of anaemia, rising commercialisation of EPO drugs and favourable reimbursement policies are further driving the market growth. As cheaper biosimilars are also available the market is expected to propel during the forecast period.
On the basis of geography, the market is analysed under various regions namely North America, Europe, Asia-Pacific and Rest of the World. The Erythropoietin Drugs Market was dominated by Europe followed closely by North America. Asia Pacific is expected to grow at a high CAGR.
Some of the major companies dominating the market, by their products and services include Johnson & Johnson, Celltrion, Inc, Teva Pharmaceutical Industries Ltd. , Sun Pharmaceutical Industries Ltd. , Dr. Reddy’s Laboratories Ltd.Amgen, Inc. , F. Hoffmann-La Roche Ltd. , LG Life Sciences Ltd. , Biocon Limited and Intas Pharmaceuticals Ltd.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: